ClinicalTrials.gg
CompletedNCT01744197Updated Oct 25, 2018Results posted

Synera Venipuncture Pain

A Phase 2 interventional study of Synera (lidocaine 70mg/tetracaine 70mg) in Pain, Phlebotomy and Palliative Care, sponsored by US Oncology Research. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Enrollment
110th of 203
61 · median 66
Started
2013
with 16 others
Phase 2
17 of 204
2 open now
Registered
75th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 110th largest by enrollment of the 203 interventional ones that give a count, is one of 17 that started in 2013, is one of 17 in phase 2, and was the 75th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine patch when administered for 30 ± 5 minutes to provide dermal anesthesia in adult oncology patients undergoing venipuncture as part of their care, for treatment or diagnostics (laboratory or imaging). Compared to the use of the placebo patch, this study hypothesizes that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30 minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS

03

Conditions studied

  • Pain
  • Phlebotomy
  • Palliative Care

Browse trials for

Keywords

  • Pain control
  • Needle stick pain
  • Venipuncture pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with any tumor type where treatment is received through venipuncture or any procedure that is needle based or who require regular pharmacokinetic (PK) study.
  • Is 18 years of age or older.
  • Patients expected to undergo the first venipuncture procedure within 5 working days of enrollment.
  • Male or female patients
  • Has signed the most recent Patient Form
  • Has signed a Patient Authorization Form (HIPPA)

Exclusion criteria

Exclusion Criteria:

  • Patients with sensitivity to lidocaine, tetracaine, or any other component of the product
  • Known sensitivity to any components of test materials (sulphites and adhesives)
  • Patients with damaged or broken skin at the designated patch site
  • Pregnant or breastfeeding women patients
  • Use of any immediate-release single-agent opioid product (ie, morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, or tramadol) or combination products containing acetaminophen or ibuprofen with one of these agents within 4 hours of the patient's visit
  • Previous irradiation to the site of the patch
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Arm 1

    First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch

    Drug: Synera (lidocaine 70mg/tetracaine 70mg)

  • Experimental
    Arm 2

    First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch

    Drug: Synera (lidocaine 70mg/tetracaine 70mg)

Interventions

  • DrugSynera (lidocaine 70mg/tetracaine 70mg)

    Drug page: Lidocaine

    All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.

    Also known as: Synera

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With No or Minor Pain (VAS<3)

    The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS \<3 is considered as patients with no or minor pain and would be compared between 2 groups.

    Time frame: 30 minutes after the venipuncture.

  2. Percentage of Patients With No Pain (VAS=0)

    The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.

    Time frame: 30 minutes after the venipuncture.

Secondary outcomes

  1. Global Assessment of Satisfaction With Venipuncture

    Rates of Satisfied and very satisfied are used to be compared between two groups.

    Time frame: 30 minutes after the venipuncture.

07

Results

Posted Feb 17, 2016

Participant flow

Participant flow — Overall Study
MilestoneSynera First, Then PlaceboPlacebo First, Then Synera
Started3229
Completed2826
Not completed43
Withdrew: Received 1 patch21
Withdrew: No patch received22

Outcome measures

PrimaryPercentage of Patients With No or Minor Pain (VAS<3)

The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS \<3 is considered as patients with no or minor pain and would be compared between 2 groups.

Time frame:
30 minutes after the venipuncture.
Reported as:
Number · percentage of participants
Percentage of Patients With No or Minor Pain (VAS<3)
percentage of participantsSyneraPlacebo
Percentage of Patients With No or Minor Pain (VAS<3)38.021.3
PrimaryPercentage of Patients With No Pain (VAS=0)

The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.

Time frame:
30 minutes after the venipuncture.
Reported as:
Number · percentage of participants
Percentage of Patients With No Pain (VAS=0)
percentage of participantsSyneraPlacebo
Percentage of Patients With No Pain (VAS=0)19.48.3
SecondaryGlobal Assessment of Satisfaction With Venipuncture

Rates of Satisfied and very satisfied are used to be compared between two groups.

Time frame:
30 minutes after the venipuncture.
Reported as:
Number · percentage of participants
Global Assessment of Satisfaction With Venipuncture
percentage of participantsSyneraPlacebo
Global Assessment of Satisfaction With Venipuncture74.053.7

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Synera—0/54 (0%)25/54 (46.3%)
Placebo—0/54 (0%)18/54 (33.3%)
Most frequent other events
Most frequent other events
EventSyneraPlacebo
WELL-DEFINED ERYTHEMASkin and subcutaneous tissue disorders14/547/54
VERY SLIGHT ERYTHEMASkin and subcutaneous tissue disorders11/5411/54

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Synera First, Then PlaceboPlacebo First, Then SyneraTotal
Mean60.8 ± 11.260.3 ± 13.060.5 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Synera First, Then PlaceboPlacebo First, Then SyneraTotal
Female201434
Male121527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Synera First, Then PlaceboPlacebo First, Then SyneraTotal
Caucasian312455
African American145
Indian011
Region of Enrollment
Region of Enrollment(participants)Synera First, Then PlaceboPlacebo First, Then SyneraTotal
United States322961
08

Study locations

1 site
  • 19 Locations Including
    Dallas, Texas, United States
09

References and documents

Publications

  • Wallace MS, Kopecky EA, Ma T, Brophy F, Campbell JC. Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):507-13. doi: 10.1097/AAP.0b013e3181fa69b8. PubMed 20975464 ↗
  • Sawyer J, Febbraro S, Masud S, Ashburn MA, Campbell JC. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth. 2009 Feb;102(2):210-5. doi: 10.1093/bja/aen364. PubMed 19151049 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Feb 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 6, 2012
Start
Jan 2013
Primary completionActual
Feb 2013
CompletionActual
Nov 2013
Results first posted
Feb 17, 2016
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01744197
Collaborators
Nuvo Research Inc.
Responsible party
Sponsor
First posted
Dec 6, 2012
Start date
Jan 2013
Primary completion
Feb 2013
Completion
Nov 2013
Results posted
Feb 17, 2016
Last update
Oct 25, 2018

Study contacts

Melanie Matson, RN, BSN
principal investigator · US Oncology Research, McKesson Specialty Health
Laura T. Guerra, RN
principal investigator · US Oncology Research, McKesson Specialty Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion